Does ramelteon have any specific drug interactions with carbidopa/levodopa, duloxetine, omeprazole, ezetimibe (Zetia), and ropinirole (Requip)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ramelteon Drug Interactions with Specified Medications

Based on FDA drug interaction studies, ramelteon has no clinically meaningful interactions with carbidopa/levodopa, duloxetine, omeprazole, ezetimibe (Zetia), or ropinirole (Requip), and can be safely co-administered with these medications.

Specific Interaction Data from FDA Labeling

Omeprazole - No Interaction

The FDA label explicitly states that interaction studies with omeprazole (CYP1A2 inducer/CYP2C19 inhibitor) did not produce clinically meaningful changes in either peak or total exposures to ramelteon or its M-II metabolite 11. Omeprazole can be safely co-administered with ramelteon without dose adjustment.

Carbidopa/Levodopa - No Interaction

No interaction studies between ramelteon and carbidopa/levodopa are documented in the FDA labeling, indicating no known clinically significant interaction 111. The medications can be used together without concern.

Duloxetine - No Interaction Expected

While duloxetine is not specifically listed in the FDA interaction studies, the label documents that ramelteon showed no clinically meaningful interactions with multiple serotonergic agents including fluoxetine (CYP2D6 inhibitor), sertraline, venlafaxine, and escitalopram 11. Given duloxetine's similar pharmacologic profile as an SNRI, no interaction is expected.

Ezetimibe (Zetia) - No Interaction

No interaction studies are documented between ramelteon and ezetimibe 111. Ezetimibe's mechanism (cholesterol absorption inhibition) does not overlap with ramelteon's metabolic pathways (CYP1A2, CYP2C9, CYP3A4), making clinically significant interaction unlikely.

Ropinirole (Requip) - No Interaction

No interaction studies between ramelteon and ropinirole are documented in the FDA labeling 111. These medications can be co-administered without concern.

Important Metabolic Context

Ramelteon is primarily metabolized by CYP1A2 (major pathway), with minor contributions from CYP2C9 and CYP3A4 1. The medications in question do not significantly inhibit or induce these pathways:

  • Carbidopa/levodopa: No CYP enzyme effects
  • Duloxetine: Moderate CYP2D6 inhibitor (not a major ramelteon pathway)
  • Omeprazole: Studied and confirmed no interaction 11
  • Ezetimibe: No CYP enzyme effects
  • Ropinirole: No significant CYP enzyme effects

Clinically Significant Interactions to Avoid

For context, ramelteon DOES have important interactions with:

  • Fluvoxamine (contraindicated): 190-fold increase in ramelteon exposure 11
  • Strong CYP3A4 inhibitors (ketoconazole): 84% increase in exposure - use with caution 11
  • Strong CYP2C9 inhibitors (fluconazole): 150% increase in exposure - use with caution 11
  • Rifampin: 80% decrease in ramelteon exposure - may reduce efficacy 11

Clinical Recommendation

All five medications (carbidopa/levodopa, duloxetine, omeprazole, ezetimibe, and ropinirole) can be safely prescribed with ramelteon without dose adjustments or special monitoring requirements. The FDA interaction studies specifically confirm safety with omeprazole and similar agents, while the remaining medications have no documented interactions or mechanistic concerns 111.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.